New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 19, 2014
08:48 EDTISISIsis CEO says APOC3 data 'really exciting,' NY Times reports
Following the publication of new studies that independently identified mutations in the APOC3 gene that protect against heart attacks, the CEO of Isis Pharmaceuticals, Stanley Crooke, whose company is developing a drug that counteracts the gene, said, "Trust me, these data are really exciting" and called the product "the most important drug" in the company's pipeline, according to The New York Times. Experts see the findings leading to a push to develop drugs that mimic the effect of the mutations, but caution that drug development takes years and that there are no guarantees that new treatments will succeed, the report noted. Shares of Isis are up 4% in pre-market trading following the study publications. Reference Link
News For ISIS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 16, 2014
07:06 EDTISISIsis Pharmaceuticals initiates phase 1/2 study of ISIS-DMPK Rx
Subscribe for More Information
December 11, 2014
09:28 EDTISISIsis Pharmaceuticals up 3% after CEO appears on Mad Money
Subscribe for More Information
December 8, 2014
10:41 EDTISISIsis Pharmaceuticals price target raised to $81 from $62 at Piper Jaffray
Subscribe for More Information
08:00 EDTISISIsis Pharmaceuticals price target raised to $66 from $55 at Stifel
Subscribe for More Information
05:30 EDTISISIsis Pharmaceuticals to host conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use